Bayesian Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,153
| Closed | -$567K | – | 308 |
|
|
2026
Q1 | $567K | Buy |
+1,153
| New | +$626K | 0.69% | 45 |
|
|
2025
Q4 | – | Sell |
-4,200
| Closed | -$2.04M | – | 513 |
|
|
2025
Q3 | $2.04M | Sell |
4,200
-2,700
| -39% | -$1.26M | 0.42% | 70 |
|
|
2025
Q2 | $2.8M | Buy |
6,900
+5,800
| +527% | +$2.43M | 0.44% | 58 |
|
|
2025
Q1 | $547K | Buy |
+1,100
| New | +$596K | 0.09% | 277 |
|
|
2024
Q4 | – | Sell |
-1,000
| Closed | -$619K | – | 996 |
|
|
2024
Q3 | $619K | Buy |
+1,000
| New | +$592K | 0.07% | 332 |
|
|
2024
Q1 | – | Sell |
-730
| Closed | -$387K | – | 1121 |
|
|
2023
Q4 | $387K | Sell |
730
-3,888
| -84% | -$1.88M | 0.04% | 439 |
|
|
2023
Q3 | $2.34M | Buy |
4,618
+3,893
| +537% | +$2.07M | 0.27% | 96 |
|
|
2023
Q2 | $378K | Buy |
+725
| New | +$391K | 0.04% | 475 |
|
|
2023
Q1 | – | Sell |
-6,700
| Closed | -$3.69M | – | 1084 |
|
|
2022
Q4 | $3.69M | Buy |
6,700
+2,122
| +46% | +$1.12M | 0.54% | 19 |
|
|
2022
Q3 | $2.32M | Buy |
4,578
+2,211
| +93% | +$1.24M | 0.47% | 39 |
|
|
2022
Q2 | $1.29M | Buy |
+2,367
| New | +$1.3M | 0.24% | 110 |
|
|
2021
Q3 | – | Sell |
-1,300
| Closed | -$656K | – | 545 |
|
|
2021
Q2 | $656K | Sell |
1,300
-2,548
| -66% | -$1.2M | 0.17% | 150 |
|
|
2021
Q1 | $1.76M | Buy |
+3,848
| New | +$1.84M | 0.4% | 53 |
|
|
2020
Q2 | – | Sell |
-2,383
| Closed | -$676K | – | 785 |
|
|
2020
Q1 | $676K | Buy |
+2,383
| New | +$751K | 0.15% | 214 |
|
|
2019
Q4 | – | Sell |
-1,217
| Closed | -$354K | – | 750 |
|
|
2019
Q3 | $354K | Sell |
1,217
-4,283
| -78% | -$1.23M | 0.07% | 331 |
|
|
2019
Q2 | $1.61M | Buy |
5,500
+1,100
| +25% | +$303K | 0.33% | 80 |
|
|
2019
Q1 | $1.2M | Sell |
4,400
-4,000
| -48% | -$995K | 0.23% | 138 |
|
|
2018
Q4 | $1.88M | Buy |
+8,400
| New | +$1.97M | 0.38% | 50 |
|
|
2018
Q3 | – | Sell |
-7,100
| Closed | -$1.47M | – | 794 |
|
|
2018
Q2 | $1.47M | Buy |
7,100
+3,100
| +78% | +$658K | 0.33% | 72 |
|
|
2018
Q1 | $826K | Sell |
4,000
-4,300
| -52% | -$903K | 0.21% | 151 |
|
|
2017
Q4 | $1.58M | Buy |
+8,300
| New | +$1.59M | 0.32% | 79 |
|
|
2017
Q3 | – | Sell |
-6,500
| Closed | -$1.13M | – | 636 |
|
|
2017
Q2 | $1.13M | Sell |
6,500
-300
| -4% | -$50.4K | 0.42% | 58 |
|
|
2017
Q1 | $1.04M | Buy |
6,800
+300
| +5% | +$45.9K | 0.5% | 35 |
|
|
2016
Q4 | $917K | Buy |
+6,500
| New | +$958K | 0.23% | 154 |
|
Other funds holding TMO
Bayesian Capital Management's TMO Position: Q2 2026 in Review
Bayesian Capital Management sold out of Thermo Fisher Scientific (TMO) in Q2 2026, closing a stake of 1,153 shares — an estimated $567K sold.
Bayesian Capital Management first reported a position in TMO in Q4 2016 and held it in 24 quarters. The position peaked at $3.69M in Q4 2022. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Bayesian Capital Management reported no remaining Thermo Fisher Scientific position as of Q2 2026 after selling out during the quarter.
- Bayesian Capital Management sold 1,153 Thermo Fisher Scientific shares in Q2 2026, an estimated $567K.
- Bayesian Capital Management first reported a position in Thermo Fisher Scientific in Q4 2016 and held it in 24 quarters.
- Bayesian Capital Management's Thermo Fisher Scientific position peaked at $3.69M in Q4 2022.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.